Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

Stopped early · Phase 2

Conditions studied: Breast Cancer, Breast Tumors

In brief

The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change in left ventricle ejection fraction (LVEF).

Key facts

Study ID
NCT02472353
Run by
Avera McKennan Hospital & University Health Center
People needed
30
Starts
2014-07-01
Expected to finish
2018-05-23
Last updated by the study team
2019-10-16

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.